Actively Recruiting

Phase 2
Age: 40Years +
All Genders
NCT07037836

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

Led by Bastiaan Driehuys · Updated on 2025-10-30

10

Participants Needed

1

Research Sites

91 weeks

Total Duration

On this page

Sponsors

B

Bastiaan Driehuys

Lead Sponsor

U

United Therapeutics

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \[DLCO\] ≥45%). The main questions it aims to answer are: 1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)? 2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \[RBC\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)? 3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil? Participants will: * Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated. * Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange. * Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study. * Be monitored for adverse events, with a phone check-in midway through and after the treatment period.

CONDITIONS

Official Title

Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Outpatients of any gender aged 40 years or older
  • Clinical evidence of chronic bronchitis with productive cough lasting more than 3 months within a 2-year period
  • Current or former smokers with at least 20 pack-years smoking history
  • Confirmed COPD diagnosis with FEV1/FVC ratio below 0.70, pre-bronchodilator FEV1 of 30% predicted or higher, and DLCO of 45% predicted or higher
  • On stable COPD maintenance medications for at least 3 months without changes
  • Presence of hypoxemia requiring supplemental oxygen at rest or during exercise at 4 liters per minute or less
  • Able and willing to provide informed consent and follow study schedules
  • Women of childbearing potential must have a negative serum pregnancy test before participation
Not Eligible

You will not qualify if you...

  • Upper respiratory tract infection within 6 weeks prior to screening
  • History of lung resection surgery or pleural decortication
  • Previous pneumothorax
  • Imaging showing interstitial lung disease, occupational lung disease, or chronic infectious lung disease
  • History of asthma
  • Exposure history to occupational or environmental hazards causing lung disease
  • Positive pregnancy test for women of childbearing potential
  • Major chronic illness that may interfere with study participation
  • Contraindications to MRI including pregnancy or lactation
  • Respiratory illness of bacterial or viral origin within 6 weeks prior to MRI
  • Known cardiac arrhythmia
  • Inability to fit into the hyperpolarized xenon-129 MRI vest coil
  • Inability to hold breath for 10 seconds during imaging
  • Unlikely to comply with instructions during MRI imaging

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Duke Asthma Allergy and Airway Center

Durham, North Carolina, United States, 27705

Actively Recruiting

Loading map...

Research Team

Y

Yuh-Chin Huang, M.D., M.H.S., MD

CONTACT

S

Savannah Barbieri

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here